CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 84 enrolled
Drug / intervention
GSK1322322 +3 moredrug
Likely dose
GSK1322322 1500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01209078
NCT01209078Phase 2Completed
CompareCT.gov

A Randomized, Double Blind, Double Dummy Multicenter Phase IIa Study to Assess Safety, Tolerability and Efficacy of GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection

GlaxoSmithKline·interventional·Posted Sep 24, 2010·Updated Dec 4, 2017

In Brief

A Phase 2 clinical trial evaluating GSK1322322, Linezolid, and 2 other interventions for Skin Infections, Bacterial. Completed, enrolled 84 participants across 7 sites.

Detailed Summary

This study will determine the safety, tolerability and efficacy of GSK1322322 verses Linezolid in subjects with Acute Bacterial Skin and Skin Structure Infection (ABSSSI).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSkin Infections, Bacterial
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 24, 2010
Enrollment StartAug 17, 2010
Primary CompletionJan 18, 2011
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 15.8 years ago

Interventions

GSK1322322drug

GSK1322322 1500mg BID

Linezoliddrug

Linezolid 600mg

GSK1322322 placebodrug

Placebo

Linezolid placebodrug

placebo